Elevated CLDN4 expression in glioma tissues are associated with poor clinical outcomes, and Yang et al. further demonstrated a positive correlation between CLDN4 expression and the more advanced clinical stages of glioma patients, what was assessed using immunohistochemical staining (IHC) (38). Here, CLDN4 is linked to central nervous system cancer.